SURVIVAL OF BARICITINIB VS ANTI-TNF AS THE FIRST BIOLOGICAL DRUG IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN CLINICAL PRACTICE: RESULTS OF A LOCAL REGISTRY Conference Paper 2022 Congress communication